OmniAb, Inc.
Donna Ventura has extensive work experience in finance and accounting roles. Donna currently holds the position of Senior Vice President, Corporate Controller at OmniAb, Inc. since July 2022. Donna also serves as an Adjunct Faculty Instructor at Moorpark College from September 2022.
Previously, Donna worked as the Vice President, Corporate Controller at Arena Pharmaceuticals, Inc. from March 2021 to May 2022. Prior to that, they served as the Assistant Chief Financial Officer at the City of Oxnard from January 2019 to March 2021, where they oversaw various accounting functions and was the primary point of contact with external auditors.
Donna spent a significant portion of their career at Amgen, where they held various executive positions. From August 2015 to May 2018, they were the Executive Director, Global Business Services. Prior to that, they served as the Executive Director, Tax from February 2010 to July 2015 and the Executive Director, Finance from February 2007 to February 2010. Donna also held the roles of Global Program Manager, Associate Director of Strategic Planning & Operations, Associate Director of Commercial FP&A, and Senior Manager of Corporate Financial Planning & Analysis during their tenure at Amgen.
Before joining Amgen, Donna worked at Atlantic Richfield Company (ARCO) as a Senior Manager in Finance from 1992 to 1999. Donna began their career at KPMG as a Supervising Senior Accountant from June 1987 to April 1992.
Donna Ventura holds a Master of Business Administration (MBA) degree with a focus on Finance and Management from UCLA Anderson School of Management. Donna also earned a Bachelor of Business Administration (BBA) degree in Accounting from Pace University. In addition to their degrees, Donna has obtained the Certified Public Accountant (CPA) certification from the State of California in October 2019.
This person is not in the org chart
This person is not in any offices
OmniAb, Inc.
The OmniAb discovery platform provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence (BI) of our proprietary transgenic animals, including OmniRat,OmniChicken and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur features unique structural attributes of cow antibodies for complex targets. OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput microfluidic-based single B cell screening and deep computational analysis of next-generation sequencing datasets to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities to further leverage across modalities, including antibody-drug conjugates and others. The OmniAb suite of technologies and differentiating computational capabilities and BI features are combined to offer a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry. For more information, please visit www.omniab.com.